Quarterly ResultAug 5, 2026, 04:17 PM
Arcus Biosciences Q2 Net Loss $91M; Discontinues Anti-TIGIT Program
AI Summary
Arcus Biosciences reported a net loss of $91 million for the second quarter of 2026, a significant decrease from break-even in the prior year, with revenues falling to $41 million from $160 million. The company announced the discontinuation of the Phase 3 PACIFIC-8 study for its anti-TIGIT program (domvanalimab) with AstraZeneca, leading to Gilead relinquishing its board seats. Despite these setbacks, Arcus is aggressively advancing its casdatifan program for clear cell renal cell carcinoma with new clinical collaborations and expects multiple data readouts in the second half of 2026, maintaining a cash runway until at least the second half of 2028.
Key Highlights
- Q2 2026 Net Loss was $91 million, compared to $0 million in Q2 2025.
- Q2 2026 Revenues were $41 million, down from $160 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $775 million as of June 30, 2026.
- Arcus expects full-year 2026 GAAP revenue between $65 million and $75 million.
- Discontinued the Phase 3 PACIFIC-8 study for domvanalimab (anti-TIGIT program) with AstraZeneca.
- Gilead relinquished its three seats on Arcus’s Board of Directors effective August 5, 2026.
- Initiated three new clinical collaborations for casdatifan-based combinations in ccRCC.
- Cash runway is projected until at least the second half of 2028.
Price Impact
More from RCUS